Found 2 clinical trials
At-Risk for Type 1 Diabetes Extension Study
This study is an extension of the NIH-sponsored AT-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who develop clinical type 1 diabetes after the conclusion of that trial, are eligible to enroll and receive teplizumab treatment within one year of diagnosis of …
- 0 views
- 19 Feb, 2024
- 5 locations
Description of Patients With Type 1 Diabetes Treated With Teplizumab (TEPLI-REAL)
Patients outside of the USA are able to receive the treatment through Pre-Registration Import Licenses and Managed Access Programs. The current study will collect data on the use of teplizumab in routine care, to better understand which patients received teplizumab and how these patients were managed after they received the …
- 0 views
- 15 May, 2025
- 2 locations